Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Merck
Moodys
Accenture
Chinese Patent Office
UBS
Federal Trade Commission
Deloitte

Generated: January 18, 2018

DrugPatentWatch Database Preview

DOXORUBICIN HYDROCHLORIDE - Generic Drug Details

« Back to Dashboard

What are the generic sources for doxorubicin hydrochloride and what is the scope of doxorubicin hydrochloride patent protection?

Doxorubicin hydrochloride
is the generic ingredient in five branded drugs marketed by Janssen Res And Dev, Dr Reddys Labs Ltd, Sun Pharma Global, Pharmacia And Upjohn, Actavis Inc, Alvogen Inc, Amneal Pharms Co, Fresenius Kabi Usa, Gland Pharma Ltd, Mylan Labs Ltd, Pharmachemie Bv, Sagent Pharms, Sandoz Inc, Sun Pharm Inds, Teva Pharms Usa, West-ward Pharms Int, and Bristol Myers Squibb, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for doxorubicin hydrochloride. Seventeen suppliers are listed for this compound.
Pharmacology for DOXORUBICIN HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for DOXORUBICIN HYDROCHLORIDE

US Patents and Regulatory Information for DOXORUBICIN HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 064140-001 Jul 28, 1995 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 050467-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb RUBEX doxorubicin hydrochloride INJECTABLE;INJECTION 062926-003 Apr 13, 1989 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 050629-001 Dec 23, 1987 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 050467-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Amneal Pharms Co DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 208888-002 Feb 17, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pharmachemie Bv DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 063336-001 Feb 28, 1995 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Fresenius Kabi Usa DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 063277-001 Oct 26, 1995 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Ltd DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 208657-001 May 15, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Labs Ltd DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 200170-002 Oct 28, 2011 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for DOXORUBICIN HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Res And Dev DOXIL (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 050718-001 Nov 17, 1995 ➤ Subscribe ➤ Subscribe
Janssen Res And Dev DOXIL (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 050718-001 Nov 17, 1995 ➤ Subscribe ➤ Subscribe
Janssen Res And Dev DOXIL (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 050718-002 Jun 13, 2000 ➤ Subscribe ➤ Subscribe
Janssen Res And Dev DOXIL (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 050718-002 Jun 13, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
US Department of Justice
Cerilliant
Daiichi Sankyo
Baxter
Boehringer Ingelheim
Chinese Patent Office
McKesson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot